CONNECTS Study Data Request
To promote data sharing and reuse, CONNECTS is making all study data publicly available for request at NHLBI BioData Catalyst (BDC). CONNECTS studies are completed at different times and we strive to release each study’s datasets shortly after the process of data cleaning, quality check, standardization, and harmonization to CONNECTS COVID-19 Therapeutic Trial Common Data Elements (CDEs). To request available study data sets, click the link in the “Data Request” column. All data is housed at BioData Catalyst and information can be found at the BioData Catalyst COVID-19 Data page. All data requests are managed by dbGAP using the links found below.
Study Number | Study Name | Data Request Status |
---|---|---|
ACTIV4a - V1.0 | ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 1 - Heparin | Released |
ACTIV4a - V1.1 | ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 2- P2Y12 Inhibitors | Released |
ACTIV4a - V1.2 | ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19, Phase 3 - Crizanlizumab, SGLT2i | Expected Spring 2024 |
ACTIV4b | COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 | Released |
ACTIV4c | COVID-19 Post-hospital Thrombosis Prevention Study | Released |
ACTIV4 Host Tissue | NECTAR: Novel Experimental COVID Therapies Affecting Host Response | TBD |
ACTIV4 Mechanistic Studies | Prothombotic Antiphosphlipid Antibodies in COVID-19 | TBD |
Antiphospholipid Antibodies in COVID-19 | TBD | |
Convergence of Apoptosis and Innate Immunity in COVID-19 Immunothrombosis | TBD | |
Mechanisms of Endotheliopathy in SARS-CoV-2 Infection | TBD | |
SARS-CoV-2 Viremia is Associated with Endothelial Injury and Increased Thrombotic Risk | TBD | |
Characterization of Fibrinolytic Homeostasis in COVID-19 | TBD | |
TF Activation in COVID-19 Associated Coagulopathy | TBD | |
Antibody Mediated Thromboinflammation in COVID-19 | TBD | |
Platelet Activity and Effector Cell Properties in COVID-19 | TBD | |
ACTIV4-BEACONS: COVID-19: Comprehensive Biomarker Analysis for Prediction of clinical course and patient treatment outcomes (COVID-BEACONS) in ACTIV-4 | TBD | |
Fibrinolysis Shutdown Underlies Advanced ARDS due to COVID-19 | TBD | |
Investigating the Relationship between Catecholamines, Renalase and Angiotensin II in the RAAS Pathway in COVID-19 Patients | TBD | |
C3PO | Clinical Trial of COVID-19 Convalescent Plasma in Outpatients | Released |
C4R: Collaborative Cohort of Cohorts for COVID-19 Research | Atherosclerosis Risk in Communities (ARIC) | Released |
REasons for Geographic and Racial Differences in Stroke (REGARDS) | Released | |
Framingham Heart Study (FHS) | Released | |
Severe Asthma Research Program (SARP) | Released | |
Northern Manhattan Study (NOMAS) | Released | |
Genetic Epidemiology of COPD Study (COPDGene) | Expected Early 2024 | |
Coronary Artery Risk Development in Young Adults (CARDIA) | Expected Early 2024 | |
Multi-Ethnic Study of Atherosclerosis (MESA) | Expected Early 2024 | |
The Mediators of Atherosclerosis in South Asians Living in America (MASALA) | Expected Early 2024 | |
Prevent Pulmonary Fibrosis (PrePF) | Expected Early 2024 | |
Hispanic Community Health Study/Study of Latinos (HCHS/SOL) | TBD | |
Jackson Heart Study (JHS) | TBD | |
Subpopulations and Intermediate Markers in COPD Study (SPIROMICS) | TBD |